ABSTRACT
OBJECTIVE@#To study the association of the level of advanced oxidation protein products (AOPPs) in seminal plasma with teratospermia and the outcome parameters of fertilization (IVF).@*METHODS@#We conducted a cross-sectional study among 272 male patients receiving assisted reproduction treatment in the Center for Reproductive Medicine of our hospital between October, 2018 and March, 2019. The levels of seminal AOPPs and reactive oxygen species (ROS), demographic data, sperm parameters and IVF outcome parameters were analyzed for all the patients. According to the percentage of sperms with normal morphology, the patients were divided before IVF into teratozoospermia group and normal sperm morphology group, and those in teratozoospermia group were further divided into 3 subgroups with mild, moderate and severe teratozoospermia. The patients were also divided on the day oocyte retrieval into 2 groups with fertilizing rates lower (group Ⅰ) and higher (group Ⅱ) than the median rate.@*RESULTS@#We found a significant negative correlation of seminal AOPP level before treatment with the percentage of normal sperm morphology (=0.003) and seminal ROS level (=0.013). The seminal levels of AOPPs (= 0.027) and ROS (=0.036) were significantly elevated in patients with teratospermia, and seminal AOPP level was significantly higher in severe teratospermia group than in mild (=0.019) and moderate (=0.015) teratospermia groups. The seminal levels of AOPPs (=0.003) and ROS (=0.017) on the day of oocyte retrieval were negatively correlated with the fertilization rate in IVF cycles, and the levels of AOPPs (=0.049) and ROS (=0.036) were significantly higher in group Ⅰ than in group Ⅱ.@*CONCLUSIONS@#An elevated level of seminal AOPPs may indicate an increased risk of severe teratospermia and a lower fertilization rate in IVF.
Subject(s)
Humans , Male , Advanced Oxidation Protein Products , Cross-Sectional Studies , Fertilization in Vitro , Semen , Spermatozoa , TeratozoospermiaABSTRACT
Estudiar el efecto del tratamiento con ácido fólico y zinc, en pacientes masculinos subfértiles, con diagnóstico de astenospermia, oligospermia y/o teratospermia. Estudio prospectivo y descriptivo. Se administró tratamiento con ácido fólico (55 mg) y zinc (550 mg) diarios, por un período de 90 días, a pacientes con alteración de la motilidad, concentración y/o morfología espermática. Servicio de Fertilidad. Maternidad Concepción Palacios . Caracas. Después de 90 días de tratamiento, la motilidad total aumento de 44,37 por ciento a 55,22 por ciento, (P=,0002). Las formas espermáticas normales pasaron de 54,11 por ciento a 55,46 por ciento (P=,0001) y las formas anormales disminuyeron e 44,29 por ciento a 4,25 (P=,0001). El tratamiento con ácido fólico y zinc, mejora significativamente la motilidad total y la morfología espermática, en el hombre sub-fértil.